Tamhane S, et al. - In individuals with congenital adrenal hyperplasia (CAH), researchers assessed the impacts of glucocorticoid therapy on cardiovascular and metabolic outcomes. In individuals with CAH treated with glucocorticoids vs controls without CAH, bibliographical databases were searched through January 2016 for studies assessing cardiovascular risk factors. The results of this systematic review and meta-analysis indicated that people with CAH show a high prevalence of cardiovascular and metabolic risk factors. However, no evidence of actual morbidity or mortality due to cardiac events was found. Individuals with CAH had increased systolic blood pressure, diastolic blood pressure, insulin resistance, and carotid intima thickness vs controls without CAH. They found no statistically significant differences in fasting blood glucose, insulin level, glucose, or insulin level after 2-hour glucose load or serum lipids.